Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian team develops simple PD (Parkinson's disease) blood test:

This article was originally published in Clinica

Executive Summary

Australian researchers from the Howard Florey Institute, in Melbourne, are developing a simple blood test for diagnosing Parkinson's disease (PD) before symptoms appear. The test, which works by measuring levels of the brain-secreted protein alpha-synuclein, is the second PD development to be announced by the group in the last few months. The team has previously said that it is developing a gene-based test for PD (see Clinica No 1252, p 23). The new test has a broader application by screening for many different types of PD, monitoring treatment, and measuring the effectiveness of drugs being developed to treat the condition. It is being trialled in a large-scale study. Funding is also being sought to further develop the test, which the group believes could become available for clinical use within the next two years.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048256

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel